Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease

OBJECTIVES: When treating Behçet’s disease (BD), anti-tumor necrosis factor (TNF)-α agents have become a second-line therapy when conventional immunosuppressive drugs have failed. However, in the case of failure of treatment with anti-TNFα drugs, further options are limited. Based on previous report...

Descripción completa

Detalles Bibliográficos
Autores principales: Arbrile, Marta, Radin, Massimo, Rossi, Daniela, Menegatti, Elisa, Baldovino, Simone, Sciascia, Savino, Roccatello, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573273/
https://www.ncbi.nlm.nih.gov/pubmed/34759935
http://dx.doi.org/10.3389/fimmu.2021.769785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573273/
https://www.ncbi.nlm.nih.gov/pubmed/34759935
http://dx.doi.org/10.3389/fimmu.2021.769785

Ejemplares similares